Hengrui Pharma(600276) 证券之星·2025-03-30 08:52Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has achieved the conditions for unlocking part of the employee stock ownership plan for 2023, marking the completion of the first lock-up period [1][3]. Group 1: Employee Stock Ownership Plan Progress - The first lock-up period of the employee stock ownership plan has been completed, and the management committee will manage the rights of the holders based on the plan and market conditions [2][3]. - The company held a temporary shareholders' meeting on November 23, 2023, to approve the employee stock ownership plan [1]. Group 2: Lock-Up Period Details - The employee stock ownership plan involves three unlocking phases: 40% after 12 months, 30% after 24 months, and 30% after 36 months from the last stock transfer [2][3]. Group 3: Performance Assessment for Unlocking - The performance assessment for unlocking includes company-level indicators such as innovative drug sales revenue, the number of new molecular entity IND approvals, and the number of NDA applications accepted [3][4]. - The first unlocking conditions require innovative drug revenue to exceed 13 billion yuan, with at least 12 IND approvals and 6 NDA applications accepted for 100% unlocking [5]. Group 4: Individual Performance Indicators - Individual performance indicators will determine the final unlocking quantity based on the company's performance metrics, with varying unlocking ratios for different employee categories [5]. - A total of 1,050 holders meet the unlocking conditions, corresponding to 4.1605 million shares, which is 0.06% of the company's total share capital [5].